Nuha Al-Hafez has has worked in the biopharmaceutical industry for more than 25 years in operations and quality in innovation, generic, and CMO sectors. Nuha was previously with Teva Canada and Patheon and joined Merck KGaA in 2014. She has covered various functions in local and global roles in quality control, quality assurance, R&D, process development, technical project management, quality risk management, product quality management, and external supplier quality including CMOs and suppliers. Nuha has been an ISPE member in Canada for many years and joined the D/A/CH Affiliate in 2019.
Just around the corner on 11-12 December, join us for a wealth of knowledge sharing, uniting industry experts to engage in discussions that unveil their insights and experiences through the 2023 ISPE Pharma 4.0™ and Annex 1 Conference.
The fourth Industrial Revolution (also known as Industry 4.0) is the era of smart machines, storage systems, and production plants that can autonomously exchange information, trigger actions, and control operations free of any human intervention. To ensure future success in the delivery of therapeutic medicines to patients, it is imperative that the pharmaceutical industry move deeper into the...
Applying emerging technologies can lead to more robust and flexible manufacturing processes that in turn can help the pharmaceutical industry respond to drug shortages, reduce interruptions in production and delivery of medicines, ensure consistent clinical performance of products, and achieve other benefits. Although some may believe that regulators are averse to the use of emerging...